Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Precision System Science Co., Ltd. (7707.T)
Matsudo, JP
Precision System Science Co., Ltd. (PSS), along with its subsidiaries, specializes in the development, production, and global distribution of automated and physicochemical instruments, software, and various related goods, serving both the Japanese domestic market and international clientele. The company's product line includes essential plastic consumables designed for its automated systems, a range of reagents, and sophisticated automated systems for nucleic acid extraction and veterinary biochemical analysis. PSS also offers geneLEAD, a specialized instrument crucial for molecular diagnostics. Furthermore, the firm is actively engaged in the research, development, and practical application within the in vitro diagnostics sector, particularly focusing on genetic and protein testing. Established in 1985, Precision System Science Co., Ltd. is headquartered in Matsudo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.43% | +5.88% | +20.00% | +8.00% | +33.66% | +42.11% | +39.18% | -22.64% | -70.43% | -30.59% | +27,521.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+17.9% ★ Q1'26: -1.6% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+77.3% ★ Q1'26: +562.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+1.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-4.9% Q1'26: +4.0% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-6.9% Q1'26: +5.1% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-0.5% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×56.07× ★ Q1'26: 2.10× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.14B
est: 5.00B (+2.9%)
|
4.46B
est: 4.40B (+1.3%)
|
3.85B
est: 4.40B (-12.6%)
|
3.64B
est: 4.00B (-9.0%)
|
4.38B
est: 4.30B (+1.9%)
|
5.07B
est: 5.00B (+1.3%)
|
9.30B
est: 9.00B (+3.3%)
|
7.43B
est: 8.00B (-7.1%)
|
5.28B
est: 8.30B (-36.4%)
|
3.98B
est: 9.00B (-55.8%)
|
4.69B
est: 4.69B (+0.0%)
|
| EBITDA |
128.66M
est: -52.23M (+346.4%)
|
-1.42B
est: -45.96M (-2,997.6%)
|
-465.35M
est: -45.96M (-912.6%)
|
-342.33M
est: -41.78M (-719.4%)
|
234.45M
est: -44.91M (+622.0%)
|
18.83M
est: -52.23M (+136.0%)
|
1.16B
est: -94.01M (+1,335.1%)
|
740.33M
est: -83.56M (+986.0%)
|
-594.05M
est: -86.69M (-585.2%)
|
-661.75M
est: -94.01M (-604.0%)
|
10.06M
est: -49.01M (+120.5%)
|
| EBIT |
-162.88M
est: -439.34M (+62.9%)
|
-1.72B
est: -386.62M (-343.8%)
|
-569.81M
est: -386.62M (-47.4%)
|
-425.68M
est: -351.47M (-21.1%)
|
148.89M
est: -377.83M (+139.4%)
|
-102.73M
est: -439.34M (+76.6%)
|
787.52M
est: -790.81M (+199.6%)
|
205.56M
est: -702.94M (+129.2%)
|
-1.24B
est: -729.31M (-69.4%)
|
-1.07B
est: -790.81M (-35.4%)
|
-228.04M
est: -412.33M (+44.7%)
|
| Net Income |
-215.22M
est: -376.63M (+42.9%)
|
-1.58B
est: -846.73M (-86.8%)
|
-555.22M
est: -786.25M (+29.4%)
|
-457.62M
est: -475.60M (+3.8%)
|
130.32M
|
-114.28M
est: 107.22M (-206.6%)
|
795.99M
est: 662.54M (+20.1%)
|
45.34M
est: 398.62M (-88.6%)
|
-1.32B
est: 448.11M (-395.5%)
|
-1.12B
est: 695.53M (-261.2%)
|
-253.10M
|
| SGA |
1.35B
est: 1.58B (-14.4%)
|
1.36B
est: 1.39B (-2.3%)
|
1.14B
est: 1.39B (-18.1%)
|
1.09B
est: 1.26B (-13.9%)
|
1.01B
est: 1.36B (-25.7%)
|
1.12B
est: 1.58B (-29.3%)
|
1.65B
est: 2.84B (-41.9%)
|
1.95B
est: 2.53B (-22.9%)
|
2.09B
est: 2.62B (-20.4%)
|
1.69B
est: 2.84B (-40.6%)
|
1.50B
est: 1.48B (+1.3%)
|
| EPS |
-11.79
est: -13.70 (+13.9%)
|
-78.29
est: -30.80 (-154.2%)
|
-26.50
est: -28.60 (+7.3%)
|
-19.84
est: -17.30 (-14.7%)
|
5.35
|
-4.41
est: 3.90 (-213.1%)
|
29.25
est: 24.10 (+21.4%)
|
1.64
est: 14.50 (-88.7%)
|
-47.93
est: 16.30 (-394.0%)
|
-40.59
est: 25.30 (-260.4%)
|
-9.21
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yoshinori Sasaki | Accounting & Finance Manager | — | — |
| Yu Sugiyama | President & Representative Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7707.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
